scholarly journals Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature

2020 ◽  
Vol 26 (7) ◽  
pp. 971-973 ◽  
Author(s):  
Melissa H Rosen ◽  
Jordan Axelrad ◽  
David Hudesman ◽  
David T Rubin ◽  
Shannon Chang
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
First Trimester ◽  
Review Of The Literature ◽  
Severe Ulcerative Colitis ◽  
Immune Mediated ◽  
First Trimester Of Pregnancy ◽  
Inflammatory Bowel ◽  
High Level

Abstract First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.

scholarly journals Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis

2016 ◽  
Vol 6 (3) ◽  
pp. 164-165
Author(s):  
NS Neki ◽  
Ankur Jain
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Adverse Effects ◽  
Bowel Disease ◽  
Modifying Agent ◽  
Immune Mediated ◽  
Established Disease ◽  
Inflammatory Bowel ◽  
Disease Modifying

Sulfasalazine is a well-established disease-modifying agent. It is commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. The most frequently reported adverse effects are gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Patients treated with sulfasalazine can develop thrombocytopenia which is immune mediated. We report a case of ulcerative colitis that was on sulfasalazine subsequently developing thrombocytopenia.J Enam Med Col 2016; 6(3): 164-165

The hazardous burden of Herpesviridae in inflammatory bowel disease: The case of refractory severe ulcerative colitis

2006 ◽  
Vol 38 (12) ◽  
pp. 887-893 ◽  
Author(s):  
A LAVAGNA ◽  
M BERGALLO ◽  
M DAPERNO ◽  
R SOSTEGNI ◽  
N RAVARINO ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Severe Ulcerative Colitis ◽  
Inflammatory Bowel

Standardizing the Care of Acute Severe Ulcerative Colitis Inpatients at an Inflammatory Bowel Disease Referral Hospital

2019 ◽  
Vol 157 (1) ◽  
pp. e32
Author(s):  
Charles Snyder ◽  
William Berk ◽  
Nicholas Genes ◽  
Brijen J. Shah ◽  
Marla C. Dubinsky
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Referral Hospital ◽  
Severe Ulcerative Colitis ◽  
Inflammatory Bowel

scholarly journals 655 – Standardizing the Care of Acute Severe Ulcerative Colitis Inpatients At an Inflammatory Bowel Disease Referral Hospital

2019 ◽  
Vol 156 (6) ◽  
pp. S-137-S-138
Author(s):  
Charles Snyder ◽  
William Berk ◽  
Nicholas Genes ◽  
Brijen J. Shah ◽  
Marla Dubinsky
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Referral Hospital ◽  
Severe Ulcerative Colitis ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document